BSX logo

BSX

Boston Scientific CorporationNYSEHealthcare
$62.82+1.32%OpenMarket Cap: $93.22B

As of 2026-04-06

Valuation

View Details

P/E (TTM)

32.26

PEG

0.58

P/B

3.84

P/S

4.64

EV/EBITDA

21.11

DCF Value

$78.78

FCF Yield

3.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

69.0%

Operating Margin

19.8%

Net Margin

14.4%

ROE

12.5%

ROA

15.7%

ROIC

8.8%

Financials

View All
PeriodRevenueNet IncomeEPS
Q4 2025$5.29B$668.0M$0.45
FY 2025$20.07B$2.89B$1.94
Q3 2025$5.07B$755.0M$0.50
Q2 2025$5.06B$793.0M$0.53

Analyst Ratings

View All
RBC CapitalOutperform
2026-03-30
NeedhamBuy
2026-03-30
Raymond JamesOutperform
2026-03-30
Goldman SachsBuy
2026-03-27
StifelBuy
2026-03-20

Trading Activity

Insider Trades

View All
Pegus Cheryldirector
SellWed Mar 04
Morano Susan Edirector
SellWed Mar 04
Weber Christophe Pierredirector
SellWed Mar 04
Weber Christophe Pierredirector
SellWed Mar 04
Smith Cathy Rdirector
SellWed Mar 04

Company Info

Sector

Healthcare

Industry

Country

US

Exchange

NYSE

Beta

0.78

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through three segments: MedSurg, Rhythm and Neuro, and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions; devices to treat various urological and pelvic conditions; implantable cardioverter and implantable cardiac resynchronization therapy defibrillators; pacemakers and implantable cardiac resynchronization therapy pacemakers; and remote patient management systems. It also provides medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising 3-D cardiac mapping and navigation solutions, ablation catheters, diagnostic catheters, mapping catheters, intracardiac ultrasound catheters, delivery sheaths, and other accessories; spinal cord stimulator systems for the management of chronic pain; indirect decompression systems; and deep brain stimulation systems. In addition, the company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; percutaneous coronary interventions products to treat atherosclerosis; intravascular catheter-directed ultrasound imaging catheters, fractional flow reserve devices, and systems for use in coronary arteries and heart chambers, as well as various peripheral vessels; and structural heart therapies. Further, it provides stents, balloon catheters, wires, and atherectomy systems to treat arterial diseases; thrombectomy and acoustic pulse thrombolysis systems, wires, and stents to treat venous diseases; and peripheral embolization devices, radioactive microspheres, ablation systems, cryotherapy ablation systems, and micro and drainage catheters to treat cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Peers